Key facts
- C the Signs’s last known valuation is $31.8M (Feb 2022).
- It has raised $21.0M; the latest was Later Stage VC ($8.0M) in Jan 2025.
- Notable investors include Plug and Play Tech Center, Khosla Ventures, Tech Nation Group, Microsoft for Startups, Matter (Consulting Services (B2B)) — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for C the Signs
- ·The full record, as it builds
Funding rounds
No funding rounds for C the Signs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About C the Signs
Developer of a cancer detection platform intended to detect cancer at the curable stage. The company's platform analyses data points, using a combination of clinical signs, symptoms, risk factors, and other markers, to spot cancer and its risk and fast-track them to an appropriate test or referral, enabling physicians to diagnose and treat cancer and reduce death rates.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2017
- Employees
- 26
- Website
- cthesigns.com/
- Ownership
- Privately Held (backing)
C the Signs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in C the Signs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on C the Signs in its N-PORT filings yet. We sweep new filings monthly.